SCHEMBL3340063

SCHEMBL3340063

CCOC(CC)OCC.NC(O)=S.NC(O)=S

nearest known ligand 0.35

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
THRB P10828 1/20 0.35
LMNA P02545 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2234391 0.81 THRB (0.32) THRBLMNA
SCHEMBL25094 0.81
SCHEMBL6380672 0.78 LMNA (0.38) THRBLMNA
Ammonia Solution, Strong SCHEMBL27897772 0.78 THRB (0.47) THRBLMNA
SCHEMBL2236324 0.77
SCHEMBL2235862 0.77 LMNA (0.63) THRBLMNA
Ethylene Glycol SCHEMBL3139436 0.76 THRB (0.40) THRBLMNA
Propanol SCHEMBL29256085 0.74 THRB (0.38) THRBLMNA
SCHEMBL6377743 0.73 PRKCA (0.30)
SCHEMBL11284590 0.71 LMNA (0.36) THRBLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1307239-A4 RADIOPHARMACEUTICAL FOR DIAGNOSTIC IMAGING CONTAINING A TECHNETIUM-99M NITRIDE HETEROCOMPLEX NIHON MEDIPHYSICS CO LTD (JP) 2005-01-26 EP claimed
US-20040018147-A1 Radiopharmaceutical for diagnostic imaging containing a technetium-99m nitride heterocomplex NIHON MEDI-PHYSICS CO., LTD. (JP) 2004-01-29 US claimed
EP-1307239-A1 RADIOPHARMACEUTICAL FOR DIAGNOSTIC IMAGING CONTAINING A TECHNETIUM-99M NITRIDE HETEROCOMPLEX Nihon Medi-Physics Co., Ltd. (JP) 2003-05-07 EP claimed
WO-2002009771-A1 RADIOPHARMACEUTICAL FOR DIAGNOSTIC IMAGING CONTAINING A TECHNETIUM-99M NITRIDE HETEROCOMPLEX NIHON MEDI-PHYSICS CO., LTD. (JP) 2002-02-07 WO claimed
US-8182789-B2 Intermediate compound of technetium nitride complex for radiodiagnostic imaging NIHON MEDI-PHYSICS CO., LTD. (JP) 2012-05-22 US disclosed
US-20100160615-A1 INTERMEDIATE COMPOUND OF TECHNETIUM NITRIDE COMPLEX FOR RADIODIAGNOSTIC IMAGING NIHON MED-PHYSICS CO., LTD. (JP) 2010-06-24 US disclosed
US-7445765-B2 Radiopharmaceutical for diagnostic imaging containing a technetium-99m nitride heterocomplex NIHON MEDI-PHYSICS CO., LTD. (JP) 2008-11-04 US disclosed
EP-1307239-A4 RADIOPHARMACEUTICAL FOR DIAGNOSTIC IMAGING CONTAINING A TECHNETIUM-99M NITRIDE HETEROCOMPLEX NIHON MEDIPHYSICS CO LTD (JP) 2005-01-26 EP disclosed
US-20040018147-A1 Radiopharmaceutical for diagnostic imaging containing a technetium-99m nitride heterocomplex NIHON MEDI-PHYSICS CO., LTD. (JP) 2004-01-29 US disclosed
EP-1307239-A1 RADIOPHARMACEUTICAL FOR DIAGNOSTIC IMAGING CONTAINING A TECHNETIUM-99M NITRIDE HETEROCOMPLEX Nihon Medi-Physics Co., Ltd. (JP) 2003-05-07 EP disclosed
WO-2002009771-A1 RADIOPHARMACEUTICAL FOR DIAGNOSTIC IMAGING CONTAINING A TECHNETIUM-99M NITRIDE HETEROCOMPLEX NIHON MEDI-PHYSICS CO., LTD. (JP) 2002-02-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100160615-A1 INTERMEDIATE COMPOUND OF TECHNETIUM NITRIDE COMPLEX FOR RADIODIAGNOSTIC IMAGING MEN1, NCDN, C1R THRB 343/4885LMNA 2957/4885
US-20040018147-A1 Radiopharmaceutical for diagnostic imaging containing a technetium-99m nitride heterocomplex SHBG, TNNT2, TNNI3 THRB 432/4885LMNA 3596/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.